|Description||DB07268 is a potent and selective JNK1 inhibitor. It has some degree of selectivity over quite a few kinases with the exceptions of CHK1, CK2, and PLK.|
SP-600125 is a specific JNK inhibitor. SP600125 kills p53-deficient cells more efficiently than their p53-proficient counterparts, in vitro. Similar observation...
CC-401 is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity. The activation of...
ATP-competitive, selective JNK inhibitor. Decreases c-Jun transcription activity and proliferation. Decreases cytochrome c release and caspase 3 activation. Sho...
Covalent modification of IRAK1 by JNK-IN-7 is a possibility and subsequent biochemical kinase assay revealed anIC50 of ~10 nM against IRAK1. JNK-IN-7 exhibited ...
The hydrochloride of Tanzisertib. Tanzisertib (CC-930) is a potent and selective JNK inhibitor which is potentially used for prevention and treatment of dermal ...
CP-457677, also called as TX006169, is a JNK inhibitor.
AS 602801 is a novel, orally active inhibitor of JNK. It blocked T-lymphocyte proliferation and induced apoptosis.
JNK Inhibitor IX
JNK inhibitor IX is a selective and potent JNK inhibitor with pIC50 of 6.5 and 6.7 for JNK2 and JNK3, respectively.
SR-3306, an aminopyrimidine derivative, is a JNK Inhibitor and could be mainly active in Phosphorylation & Dephosphorylation actions.
DB07268 is a potent and selective JNK1 inhibitor. It has some degree of selectivity over quite a few kinases with the exceptions of CHK1, CK2, and PLK.
JNK-IN-8 inhibits c-Jun phosphorylation in HeLa and A375 cells with EC50 of 486 nM and 338 nM, respectively.
IQ-1S free acid
IQ-1S free acid is a potent, selective c-Jun N-Terminal Kinase inhibitor with a preference for JNK3 (IC50=390, 360 and 87 nM for JNK1, 2 and 3 respectively). In...
Tanzisertib, also known as CC-930, is a potent, selective, and orally active JNK inhibitor with potential antifibrotic activity. CC-930 entered Phase I clinica...